Clinical Trials
13 trialsNCT04892173 2026-06-05
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Johnson & Johnson Enterprise Innovation Inc.
Phase 3 Recruiting
NCT05910827 2026-05-27
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Phase 1/2 Recruiting
NCT06064877 2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT02499120 2023-09-08
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Pfizer
Phase 2 Completed
NCT02252042 2023-07-17
MK-3475-040
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03109158 2019-04-29
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NanoCarrier Co., Ltd.
Phase 1/2 Completed
NCT02205398 2019-01-22
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Novartis
Phase 1 Terminated
NCT02633800 2019-01-07
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Daiichi Sankyo
Phase 2 Terminated
NCT01252628 2018-05-16
Phase 1 and 2 Study of PX-866 and Cetuximab
Seagen Inc.
Phase 1/2 Completed
NCT01142869 2017-05-08
An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Merck KGaA, Darmstadt, Germany
Terminated
NCT00514943 2016-07-26
BIBW 2992 (Afatinib) in Head & Neck Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT01075841 2014-07-02
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
Merck KGaA, Darmstadt, Germany
Withdrawn